SXSW 2025
The Future of Mental Health: Precision Neuromedicine
Description:
Dive into the world of cutting-edge neuroscience, brain imaging and diagnostics, bioelectronic medicine and psychedelic-inspired therapeutics. An investor and three leaders in brain health will explore the evolving realm of precision neuromedicine, what's tracking as real step change in underlying science and engineering in neuroscience (and what's not), and how once insurmountable challenges in dealing with mental health issues are now on the verge of being solved because of said applied innovation. Join us in unpacking these new avenues in neuro and what it means for patients.
Related Media
Other Resources / Information
• Designing novel psychedelic compounds with Sam Banister and Focalpoint’s Brom Rector: https://www.youtube.com/watch?v=VF8VaYyXZMA&pp=ygURc2FtIGJhbmlzdGVyIGJyb20%3D
• Kernel’s CEO Ryan Field talks about precision biomarkers and Kernel’s technology: https://community.hlth.com/events/hltheu24/sessions/decode-detect-and-defy-expectations-for-digital-biomarkers
Takeaways
- Technologies enabling precision neuromedicine will force the pharma industry to adopt more effective ad precise strategies for psychiatric drugs.
- Bioelectronic medicine and other non-pharmacologic interventions can be safer and more effective than traditional psychiatric drugs.
- A new type of brain imaging called td-fNIRS can help predict which interventions a patient will best respond to before they begin a treatment.
Speakers
- Samantha (Sam) Tabone, Partner, Focalpoint Partners
- Ryan Field, Chief Executive/Technology Officer, Kernel
- Jacob Robinson, Co-founder and Chief Executive Officer, Motif Neurotech
- Samuel (Sam) Banister, Co-founder and Chief Scientific Officer, Psylo
Organizer
Samantha Tabone, Partner, Focalpoint Partners
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments